Pharmaceuticals
Fanapt Receives FDA Approval for Bipolar I Disorder Treatment
Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food...
AbbVie to Acquire Landos Biopharma: Advancing Novel Oral Therapies for Autoimmune Diseases
AbbVie's Acquisition of Landos Marks a Strategic Move in Autoimmune Disease Treatment Development AbbVie Inc. (ABBV) has announced a definitive...
IGC Pharma’s IGC-AD1 Shows Promising Results in Alzheimer’s Agitation Trial
Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase...
FDA Delays Decision on Eli Lilly’s Alzheimer’s Drug, Donanemab
Eli Lilly's anticipation for the Food and Drug Administration's approval decision regarding its Alzheimer's treatment, donanemab, faces a setback as...
AbbVie Plans $13 Billion Bond Sale for Acquisitions
According to Bloomberg News sources familiar with the matter, AbbVie is gearing up to sell a minimum of $13 billion...
Prestige Consumer Healthcare Posts Strong Q3 Fiscal 2024 Results
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported robust financial results for its third quarter and first nine months ending December...
BioNTech and Autolus Forge Strategic Partnership to Propel CAR-T Cell Therapy Pipeline
In a significant development within the biopharmaceutical sector, BioNTech SE and Autolus Therapeutics plc have announced a strategic collaboration aimed...
Regenxbio’s RGX-121 Trial Achieves Major Milestone in Hunter Syndrome Treatment
Regenxbio Inc. (Nasdaq: RGNX) has announced significant progress in its Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of...
